Welcome to our dedicated page for Predictmedix news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Predictmedix stock.
Predictmedix AI Inc. (PMEDF) is a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI). The company recently announced a partnership with KGK Science, a renowned name in clinical research, to advance health research and product development. This collaboration aims to introduce transformative changes in healthcare innovation, particularly in clinical trial efficiency and health product development. By leveraging Predictmedix AI's cutting-edge technologies and KGK Science's expertise, the partnership is set to redefine health assessment methodologies and outcomes.
KGK Science, with over 22 years of experience, is known for its expertise in clinical research and regulatory support for nutraceutical, cannabis, and hemp industries. On the other hand, Predictmedix AI's Safe Entry Stations utilize multispectral cameras to predict a variety of health issues, including vital parameters, drug impairment, fatigue, and mental illnesses. Together, these companies are focused on enhancing health research and product development through innovative technologies and creating impactful advancements in healthcare solutions.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) announced the results of a study on its AI technology for detecting alcohol and cannabis impairment, showing efficacy rates of 79-87% and 76-92% respectively. The company plans a clinical trial in February 2022 at a North American hospital to validate these findings further. The AI system is designed to be contactless, cost-effective, and capable of immediate results. Predictmedix is also seeking classification of its technology as a class II medical device in the US.
Predictmedix Inc. (CSE: PMED, OTCQB: PMEDF) announced the first placement of its Safe Entry Station at Ste. Anne's Spa in Ontario, enhancing health and safety for staff and guests. This collaboration with partners Juiceworks Exhibits and SBL Testing Technologies highlights Predictmedix's entry into the hospitality sector as demand for safe experiences rises amid ongoing COVID-19 challenges. The Safe Entry Station is designed to identify symptoms of infectious diseases, adding a crucial layer of safety in public spaces.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) announced the successful launch of the ThuraPass Safe Entry Program at the 2021 Formula One United States Grand Prix. This program employs rapid AI-powered health screening technology to identify COVID-19 symptoms among event staff and attendees. During its first major deployment, over 400,000 people attended the event, and several staff members were flagged and sent home for recovery. The screening process takes about three seconds, enhancing safety in enclosed hospitality areas. This initiative aims to provide risk mitigation as indoor events resume.
Predictmedix Inc. has successfully deployed 15 Safe Entry Stations at the 2021 Formula 1 Aramco United States Grand Prix in Austin, Texas, aimed at enhancing health safety for attendees and catering staff. This deployment marks a significant revenue-generating initiative in partnership with JUICEWORKS EXHIBITS and CONNECTUS Global. The AI-powered stations quickly screen for COVID-19 symptoms, ensuring that only healthy individuals access hospitality areas. With over 100,000 attendees expected, this showcases Predictmedix's growing presence in the health screening market.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has successfully cleared SEC comments on its Form 20-F registration statement, submitted on June 17, 2021. This registration allows Predictmedix to list equity securities on a U.S. national stock exchange, thus enhancing its reporting and transparency. It is now required to file regular reports with the SEC, providing investors with insights into its business strategies, risk factors, and financial performance. The company aims for further capital market activities to generate long-term value for its shareholders.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) has announced a strategic partnership with Entertainment Bay, a major event production company in India. This collaboration aims to deploy Safe Entry Stations at Entertainment Bay events, enhancing health screening for infectious diseases like COVID-19. With over 100 events managed annually, Predictmedix anticipates generating approximately $1,000 per unit per day. The partnership is expected to significantly expand Predictmedix's footprint in the Indian live event market, promoting safer event environments.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) announced its participation at the LD Micro Main Event investor conference from October 12-14, 2021, in Los Angeles, California. Chief Operating Officer Dr. Rahul Kushwah will present on October 12 at 2:00 p.m. Eastern time and will engage in one-on-one investor meetings. The company specializes in rapid health screening solutions using AI to identify health issues, including COVID-19 and substance impairments. A live audio webcast of the presentation will be available online.
Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) will present at the Benzinga Healthcare Small Cap Conference virtually on September 29, 2021. Dr. Rahul Kushwah, COO, will host a presentation at 11:10 a.m. Eastern time. The conference focuses on rapid health screening solutions using AI technology to detect health issues including COVID-19. Interested parties can access the presentation via this link.
Predictmedix offers AI-powered health screening and remote patient care services worldwide.
FAQ
What is the current stock price of Predictmedix (PMEDF)?
What is the market cap of Predictmedix (PMEDF)?
What is Predictmedix AI Inc. known for?
Who is KGK Science and what expertise do they bring to the partnership?
What are the key focus areas of the partnership between Predictmedix AI Inc. and KGK Science?
How do Predictmedix AI's Safe Entry Stations contribute to the partnership?
What are the expected outcomes of the collaboration between Predictmedix AI Inc. and KGK Science?
